Name
#47 Short-interval adjunctive 5-FU application in odontogenic keratocyst treatment: A case report
Speakers
Content Presented On Behalf Of:
Army
Session Type
Poster
Date
Tuesday, March 3, 2026
Start Time
5:00 PM
End Time
7:00 PM
Location
Prince Georges Expo Hall E
Focus Areas/Topics
Clinical Care
Learning Outcomes
• Participants will be able to list three characteristics of odontogenic keratocysts (OKC) that contribute to their high rate of recurrence.
• Participants will be able to relate surgical and adjunctive therapies with corresponding OKC rate of recurrence.
• Participants will be able to recite the mechanisms of action associated with 5-Fluorouracil.
• Participants will be able to describe necessary future directions of research for short-interval 5-FU applications in the treatment of OKC.
• Participants will be able to relate surgical and adjunctive therapies with corresponding OKC rate of recurrence.
• Participants will be able to recite the mechanisms of action associated with 5-Fluorouracil.
• Participants will be able to describe necessary future directions of research for short-interval 5-FU applications in the treatment of OKC.
Session Currently Live
Description
Odontogenic keratocysts (OKCs) are developmental cysts that originate from cellular remnants of the dental lamina and are characterized by a high rate of post-surgical recurrence. Chemical adjuncts such as Carnoy’s solution or cryotherapy can lower recurrence but introduce risks such as neurotoxicity and bone necrosis. Topical 5-fluorocuracil (5-FU) has emerged as an alternative, typically delivered over a 24-hour period on ribbon-gauze packing, which requires patient compliance with close post-operative follow-up. This case describes using a short-interval, intraoperative, 5-FU application as an adjunct to standard surgery. A left-sided mandibular body OKC in a 75-year-old male was treated with enucleation and curettage plus peripheral ostectomy. A 5% 5-FU cream was applied on cotton applicator tips to the cyst cavity and allowed to dwell for less than 15 minutes, followed by copious saline irrigation and suction to remove. The defect was then grafted with particulate corticocancelleous allograft and a resorbable membrane, and then primary closure was obtained. Serial imaging demonstrated progressive bone fill at 2 months and 15 months post-surgery with no clinical or radiographic evidence of recurrence. A short-interval 5-FU protocol may capture the anti-proliferative benefits of 5-FU while avoiding the patient inconvenience and risks associated with leaving packing material in a surgical site. This case demonstrates that a less than 15-minute application of 5-FU can be safely integrated with peripheral ostectomy and grafting in the successful treatment of OKCs. Prospective studies with larger cohorts and longer surveillance are warranted to compare recurrence, morbidity, and cost-effectiveness against 24-hour 5-FU protocols.